Skip to main content
Erschienen in: Heart and Vessels 6/2019

02.01.2019 | Original Article

Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction

verfasst von: Shinji Nemoto, Yusuke Kasahara, Kazuhiro P. Izawa, Satoshi Watanabe, Kazuya Yoshizawa, Naoya Takeichi, Kentaro Kamiya, Norio Suzuki, Kazuto Omiya, Atsuhiko Matsunaga, Yoshihiro J. Akashi

Erschienen in: Heart and Vessels | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Resting heart rate (HR) plus 20 or 30 beats per minute (bpm), i.e., a simplified substitute for HR at the anaerobic threshold (AT), is used as a tool for exercise prescription without cardiopulmonary exercise testing data. While resting HR plus 20 bpm is recommended for patients undergoing beta-blocker therapy, the effects of specific beta blockers on HR response to exercise up to the AT (ΔAT HR) in patients with subacute myocardial infarction (MI) are unclear. This study examined whether carvedilol treatment affects ΔAT HR in subacute MI patients. MI patients were divided into two age- and sex-matched groups [carvedilol (+), n = 66; carvedilol (−), n = 66]. All patients underwent cardiopulmonary exercise testing at 1 month after MI onset. ΔAT HR was calculated by subtracting resting HR from HR at AT. ΔAT HR did not differ significantly between the carvedilol (+) and carvedilol (−) groups (35.64 ± 9.65 vs. 34.67 ± 11.68, P = 0.604). Multiple regression analysis revealed that old age and heart failure after MI were significant predictors of lower ΔAT HR (P = 0.039 and P = 0.013, respectively), but not carvedilol treatment. Our results indicate that carvedilol treatment does not affect ΔAT HR in subacute MI patients. Therefore, exercise prescription based on HR plus 30 bpm may be feasible in this patient population, regardless of carvedilol use, without gas-exchange analysis data.
Literatur
1.
Zurück zum Zitat Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116:682–692CrossRefPubMed Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116:682–692CrossRefPubMed
2.
Zurück zum Zitat JCS Joint Working Group (2013) Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J 77:231–248CrossRef JCS Joint Working Group (2013) Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J 77:231–248CrossRef
3.
Zurück zum Zitat Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635–1701CrossRefPubMed Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635–1701CrossRefPubMed
4.
Zurück zum Zitat Adachi H, Koike A, Obayashi T, Umezawa S, Aonuma K, Inada M, Korenaga M, Niwa A, Marumo F, Hiroe M (1996) Does appropriate endurance exercise training improve cardiac function in patients with prior myocardial infarction? Eur Heart J 17:1511–1521CrossRefPubMed Adachi H, Koike A, Obayashi T, Umezawa S, Aonuma K, Inada M, Korenaga M, Niwa A, Marumo F, Hiroe M (1996) Does appropriate endurance exercise training improve cardiac function in patients with prior myocardial infarction? Eur Heart J 17:1511–1521CrossRefPubMed
5.
Zurück zum Zitat Wasserman K, Beaver WL, Whipp BJ (1990) Gas exchange theory and the lactic acidosis (anaerobic) threshold. Circulation 81:II14-II30CrossRefPubMed Wasserman K, Beaver WL, Whipp BJ (1990) Gas exchange theory and the lactic acidosis (anaerobic) threshold. Circulation 81:II14-II30CrossRefPubMed
6.
Zurück zum Zitat JCS Joint Working Group (2014) Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J 78:2022–2093CrossRef JCS Joint Working Group (2014) Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J 78:2022–2093CrossRef
7.
Zurück zum Zitat Keteyian SJ (2017) Exercise prescription for patients with cardiac, peripheral, cerebrovascular, and pulmonary disease. In: Pescatello LS, Arena R, Riebe D, Thompson PD (eds) ACSM's guidelines for exercise testing and prescription. Lippincott Williams & Wilkins, Philadelphia, pp 226–245 Keteyian SJ (2017) Exercise prescription for patients with cardiac, peripheral, cerebrovascular, and pulmonary disease. In: Pescatello LS, Arena R, Riebe D, Thompson PD (eds) ACSM's guidelines for exercise testing and prescription. Lippincott Williams & Wilkins, Philadelphia, pp 226–245
8.
Zurück zum Zitat Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390CrossRefPubMed Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390CrossRefPubMed
9.
Zurück zum Zitat Diaz-Buschmann I, Jaureguizar KV, Calero MJ, Aquino RS (2014) Programming exercise intensity in patients on beta-blocker treatment: the importance of choosing an appropriate method. Eur J Prev Cardiol 21:1474–1480CrossRefPubMed Diaz-Buschmann I, Jaureguizar KV, Calero MJ, Aquino RS (2014) Programming exercise intensity in patients on beta-blocker treatment: the importance of choosing an appropriate method. Eur J Prev Cardiol 21:1474–1480CrossRefPubMed
10.
Zurück zum Zitat Yamamoto A, Tanabe K, Yokoyama Y, Itoh H, Murayama M (1998) Influence of aerobic exercise training on brain natriuretic peptide secretion in patients in the chronic phase of myocardial infarction. Jpn Circ J 62:658–664CrossRefPubMed Yamamoto A, Tanabe K, Yokoyama Y, Itoh H, Murayama M (1998) Influence of aerobic exercise training on brain natriuretic peptide secretion in patients in the chronic phase of myocardial infarction. Jpn Circ J 62:658–664CrossRefPubMed
11.
Zurück zum Zitat Hanson P (2012) Clinical exercise testing. In: Thompson WR, Gordon NF, Pescatello LS (eds) American College of Sports Medicine, Resource Manual for Guidelines for Exercise Testing and Prescription. Lea & Febiger, Philadelphia, pp 205–222 Hanson P (2012) Clinical exercise testing. In: Thompson WR, Gordon NF, Pescatello LS (eds) American College of Sports Medicine, Resource Manual for Guidelines for Exercise Testing and Prescription. Lea & Febiger, Philadelphia, pp 205–222
12.
Zurück zum Zitat Beaver WL, Wasserman K, Whipp BJ (1986) A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol (1985) 60:2020–2027CrossRef Beaver WL, Wasserman K, Whipp BJ (1986) A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol (1985) 60:2020–2027CrossRef
13.
Zurück zum Zitat Strzelczyk TA, Quigg RJ, Pfeifer PB, Parker MA, Greenland P (2001) Accuracy of estimating exercise prescription intensity in patients with left ventricular systolic dysfunction. J Cardiopulm Rehabil 21:158–163CrossRefPubMed Strzelczyk TA, Quigg RJ, Pfeifer PB, Parker MA, Greenland P (2001) Accuracy of estimating exercise prescription intensity in patients with left ventricular systolic dysfunction. J Cardiopulm Rehabil 21:158–163CrossRefPubMed
16.
Zurück zum Zitat Kasahara Y, Izawa K, Omiya K, Osada N, Watanabe S, Saitoh M, Matsunaga A, Masuda T (2006) Influence of autonomic nervous dysfunction characterizing effect of diabetes mellitus on heart rate response and exercise capacity in patients undergoing cardiac rehabilitation for acute myocardial infarction. Circ J 70:1017–1025CrossRefPubMed Kasahara Y, Izawa K, Omiya K, Osada N, Watanabe S, Saitoh M, Matsunaga A, Masuda T (2006) Influence of autonomic nervous dysfunction characterizing effect of diabetes mellitus on heart rate response and exercise capacity in patients undergoing cardiac rehabilitation for acute myocardial infarction. Circ J 70:1017–1025CrossRefPubMed
17.
Zurück zum Zitat Peel C, Mossberg KA (1995) Effects of cardiovascular medications on exercise responses. Phys Ther 75:387–396CrossRefPubMed Peel C, Mossberg KA (1995) Effects of cardiovascular medications on exercise responses. Phys Ther 75:387–396CrossRefPubMed
18.
Zurück zum Zitat Ozemek C, Whaley MH, Finch WH, Kaminsky LA (2016) High cardiorespiratory fitness levels slow the decline in peak heart rate with age. Med Sci Sports Exerc 48:73–81CrossRefPubMed Ozemek C, Whaley MH, Finch WH, Kaminsky LA (2016) High cardiorespiratory fitness levels slow the decline in peak heart rate with age. Med Sci Sports Exerc 48:73–81CrossRefPubMed
19.
Zurück zum Zitat Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, Weaver R, Ahmed I, Frenneaux M (2010) Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 3:29–34CrossRefPubMed Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, Weaver R, Ahmed I, Frenneaux M (2010) Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 3:29–34CrossRefPubMed
20.
Zurück zum Zitat Hogarth AJ, Mackintosh AF, Mary DA (2006) The sympathetic drive after acute myocardial infarction in hypertensive patients. Am J Hypertens 19:1070–1076CrossRefPubMed Hogarth AJ, Mackintosh AF, Mary DA (2006) The sympathetic drive after acute myocardial infarction in hypertensive patients. Am J Hypertens 19:1070–1076CrossRefPubMed
21.
Zurück zum Zitat Tabet JY, Meurin P, Driss AB, Thabut G, Weber H, Renaud N, Odjinkem N, Solal CA (2006) Determination of exercise training heart rate in patients on beta-blockers after myocardial infarction. Eur J Cardiovasc Prev Rehabil 13:538–543CrossRefPubMed Tabet JY, Meurin P, Driss AB, Thabut G, Weber H, Renaud N, Odjinkem N, Solal CA (2006) Determination of exercise training heart rate in patients on beta-blockers after myocardial infarction. Eur J Cardiovasc Prev Rehabil 13:538–543CrossRefPubMed
22.
Zurück zum Zitat Reed JL, Blais AZ, Keast ML, Pipe AL, Reid RD (2017) Performance of fixed heart rate increment targets of 20 vs 30 beats per minute for exercise rehabilitation prescription in outpatients with heart failure. Can J Cardiol 33:777–784CrossRefPubMed Reed JL, Blais AZ, Keast ML, Pipe AL, Reid RD (2017) Performance of fixed heart rate increment targets of 20 vs 30 beats per minute for exercise rehabilitation prescription in outpatients with heart failure. Can J Cardiol 33:777–784CrossRefPubMed
23.
Zurück zum Zitat Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, Nakagawa Y, Izumi C, Kadota K, Ikeguchi S, Hibi K, Furukawa Y, Kaji S, Suzuki T, Akao M, Inada T, Hayashi Y, Nanasato M, Okutsu M, Kametani R, Sone T, Sugimura Y, Kawai K, Abe M, Kaneko H, Nakamura S, Kimura T (2018) Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS ONE 13:e0199347CrossRefPubMedPubMedCentral Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, Nakagawa Y, Izumi C, Kadota K, Ikeguchi S, Hibi K, Furukawa Y, Kaji S, Suzuki T, Akao M, Inada T, Hayashi Y, Nanasato M, Okutsu M, Kametani R, Sone T, Sugimura Y, Kawai K, Abe M, Kaneko H, Nakamura S, Kimura T (2018) Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS ONE 13:e0199347CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Saito M, Kawana J, Ohno T, Hanada K, Kaneko M, Mihara K, Shiomi M, Nagayama M, Sumiyoshi T, Ogata H (2010) Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol Pharm Bull. 33:1378–1384CrossRefPubMed Saito M, Kawana J, Ohno T, Hanada K, Kaneko M, Mihara K, Shiomi M, Nagayama M, Sumiyoshi T, Ogata H (2010) Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol Pharm Bull. 33:1378–1384CrossRefPubMed
25.
Zurück zum Zitat Hakusui H, Fujimaki M (1988) Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs 36:144–147CrossRef Hakusui H, Fujimaki M (1988) Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs 36:144–147CrossRef
26.
Zurück zum Zitat Neugebauer G, Gabor M, Reiff K (1988) Pharmacokinetics and bio-availability of carvedilol in patients with liver cirrhosis. Drugs 36:148–154CrossRef Neugebauer G, Gabor M, Reiff K (1988) Pharmacokinetics and bio-availability of carvedilol in patients with liver cirrhosis. Drugs 36:148–154CrossRef
27.
Zurück zum Zitat Hori M, Nagai R, Izumi T, Matsuzaki M (2014) Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 29:238–247CrossRefPubMed Hori M, Nagai R, Izumi T, Matsuzaki M (2014) Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 29:238–247CrossRefPubMed
28.
Zurück zum Zitat Vittorio TJ, Zolty R, Kasper ME, Khandwalla RM, Hirsh DS, Tseng CH, Jorde UP, Ahuja K (2008) Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. J Cardiovasc Pharmacol Ther 13:51–57CrossRefPubMed Vittorio TJ, Zolty R, Kasper ME, Khandwalla RM, Hirsh DS, Tseng CH, Jorde UP, Ahuja K (2008) Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. J Cardiovasc Pharmacol Ther 13:51–57CrossRefPubMed
Metadaten
Titel
Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction
verfasst von
Shinji Nemoto
Yusuke Kasahara
Kazuhiro P. Izawa
Satoshi Watanabe
Kazuya Yoshizawa
Naoya Takeichi
Kentaro Kamiya
Norio Suzuki
Kazuto Omiya
Atsuhiko Matsunaga
Yoshihiro J. Akashi
Publikationsdatum
02.01.2019
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 6/2019
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-018-01326-5

Weitere Artikel der Ausgabe 6/2019

Heart and Vessels 6/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.